HUYABIO International today announced favorable Phase 1 clinical data for HBI-3000, a novel bioinspired investigational drug with promising antiarrhythmic properties, excellent tolerability and a ...

AP31969 is a novel, first-in-class, oral SK ion channel inhibitor intended for rhythm control of atrial fibrillation and has recently completed Phase 1 in healthy volunteers ...

Medications are the first-line treatment for atrial fibrillation, or A-fib. When they begin to fail, one option is ablation.

A research group led by Assistant Professor Megumi Aimoto and Professor Akira Takahara at the Faculty of Pharmaceutical Sciences, Toho University, revealed that pyrazole-3 (Pyr3), a selective ...

Please provide your email address to receive an email when new articles are posted on . A novel SK ion channel inhibitor more often converted atrial fibrillation to sinus rhythm compared with placebo.

A new study by researchers at the University of Arizona College of Medicine – Phoenix and the University of California Davis Health identified a new target for developing a therapy to treat atrial ...

Despite being the most common form of cardiac arrhythmia, atrial fibrillation (AFib) is a condition that often goes undiagnosed and/or untreated. The condition, which often accompanies other health ...

Share on Pinterest New research suggests that there may be more than 10.5 million people in the United States living with atrial fibrillation, that is, three times more cases than experts had ...

A brand new procedure to treat atrial fibrillation is now being offered at several hospitals across Colorado after UCHealth in Loveland successfully completed the first procedure in the state. c "Afib ...

Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.